No connection

Search Results

CTEV vs SRTA

CTEV
Claritev Corporation
BEARISH
Price
$23.81
Market Cap
$404.0M
Sector
Healthcare
AI Confidence
85%
SRTA
Strata Critical Medical, Inc.
BEARISH
Price
$4.57
Market Cap
$397.5M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
CTEV
--
SRTA
--
Forward P/E
CTEV
3.48
SRTA
--
P/B Ratio
CTEV
-2.27
SRTA
1.09
P/S Ratio
CTEV
0.42
SRTA
2.02
EV/EBITDA
CTEV
9.35
SRTA
-59.49

Profitability

Gross Margin
CTEV
73.75%
SRTA
20.86%
Operating Margin
CTEV
9.77%
SRTA
-5.34%
Profit Margin
CTEV
-29.45%
SRTA
20.97%
ROE
CTEV
--
SRTA
-8.01%
ROA
CTEV
1.12%
SRTA
-2.71%

Growth

Revenue Growth
CTEV
6.2%
SRTA
83.5%
Earnings Growth
CTEV
--
SRTA
--

Financial Health

Debt/Equity
CTEV
--
SRTA
0.01
Current Ratio
CTEV
0.86
SRTA
6.38
Quick Ratio
CTEV
0.6
SRTA
5.11

Dividends

Dividend Yield
CTEV
--
SRTA
--
Payout Ratio
CTEV
0.0%
SRTA
0.0%

AI Verdict

CTEV BEARISH

CTEV exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a negative Price-to-Book ratio of -2.27, indicating negative shareholder equity. While the company maintains strong gross margins (73.75%) and a low Price-to-Sales ratio (0.42), these are overshadowed by catastrophic earnings volatility and a 5-year price collapse of 91.9%. The current liquidity position is precarious with a current ratio of 0.86, suggesting an inability to cover short-term obligations. Despite bullish analyst targets, the deterministic data points to a high-risk value trap.

Strengths
Strong Gross Margin of 73.75%
Positive Operating Margin of 9.77%
Low Price-to-Sales ratio (0.42) suggesting undervaluation relative to revenue
Risks
Negative Book Value (P/B -2.27) indicating insolvency risk
Weak Piotroski F-Score (2/9) signaling deteriorating fundamental health
Liquidity risk with Current Ratio (0.86) and Quick Ratio (0.60) below 1.0
SRTA BEARISH

SRTA exhibits a critical fundamental disconnect, highlighted by a Piotroski F-Score of 0/9, indicating severe deterioration across all financial health dimensions. While the company shows impressive top-line revenue growth (83.5% YoY) and maintains a strong liquidity position (Current Ratio 6.38), it remains operationally unprofitable with a negative operating margin of -5.34%. The combination of consistent earnings misses, bearish insider selling, and a total failure in deterministic health scoring outweighs the optimistic analyst target price.

Strengths
Exceptional YoY revenue growth of 83.50%
Strong short-term liquidity with a Current Ratio of 6.38
Very low leverage with a Debt/Equity ratio of 0.01
Risks
Catastrophic Piotroski F-Score (0/9) signaling fundamental weakness
Negative operating margins indicating the core business is not self-sustaining
Severe earnings disappointments with an average surprise of -324.21% over the last 4 quarters

Compare Another Pair

CTEV vs SRTA: Head-to-Head Comparison

This page compares Claritev Corporation (CTEV) and Strata Critical Medical, Inc. (SRTA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile